Literature DB >> 17523077

The role of conjunctival epithelial cell xanthine oxidoreductase/xanthine oxidase in oxidative reactions on the ocular surface of dry eye patients with Sjögren's syndrome.

J Cejková1, T Ardan, K Jirsová, G Jechová, J Malec, Z Simonová, C Cejka, M Filipec, D Dotrelová, B Brunová.   

Abstract

Previous papers examined lipid peroxidase levels and myeloperoxidase activity as products of oxidative and inflammatory reactions in the tear fluid of patients suffering from dry eye. The aim of the present paper was to investigate whether the enzymes xanthine oxidoreductase/xanthine oxidase known to generate reactive oxygen species contribute to oxidative reactions on the ocular surface. Xanthine oxidoreductase/xanthine oxidase were examined immunohistochemically as well as histochemically in conjunctival epithelial cells of patients suffering from dry eye. Patients with verified autoimmune dry eye (Sjögren's syndrome) participated in our study; normal eyes served as controls. Conjunctival epithelial cells were obtained by the method of impression cytology using Millicell membranes. The results revealed a pronounced expression, as well as activity of xanthine oxidoreductase/xanthine oxidase in the conjunctival epithelium of dry eye. It is suggested that reactive oxygen species which are generated by this enzymatic system, contribute to oxidative reactions on the eye surface of patients with ocular manifestations of autoimmune disease (Sjögren's syndrome).

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17523077     DOI: 10.14670/HH-22.997

Source DB:  PubMed          Journal:  Histol Histopathol        ISSN: 0213-3911            Impact factor:   2.303


  4 in total

1.  Xanthine oxidase enzyme activity in keratoconic corneal epithelium.

Authors:  Burak Tanriverdi; Ozge Sarac; Hikmet Can Cubukcu; Mehtap Caglayan; Zahide Esra Durak; Ilker Durak; Nurullah Cagil
Journal:  Int Ophthalmol       Date:  2021-01-03       Impact factor: 2.031

Review 2.  Effects of Aging in Dry Eye.

Authors:  Cintia S de Paiva
Journal:  Int Ophthalmol Clin       Date:  2017

3.  A Randomized Double-Masked Phase 2a Trial to Evaluate Activity and Safety of Topical Ocular Reproxalap, a Novel RASP Inhibitor, in Dry Eye Disease.

Authors:  David Clark; John Sheppard; Todd C Brady
Journal:  J Ocul Pharmacol Ther       Date:  2021-01-15       Impact factor: 2.671

4.  A new antioxidant made from a pterostilbene functionalized graphene nanocomposite as an efficient treatment for dry eye disease.

Authors:  Mimi Lin; Xueqin Sun; Sihao Ye; Youyi Chen; Jing Gao; Feng Yuan; Na Lin; Tom Lawson; Yong Liu; Ruzhi Deng
Journal:  Front Chem       Date:  2022-08-24       Impact factor: 5.545

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.